Cerity Partners
PTCT icon

Cerity Partners’s PTC Therapeutics PTCT Stock Holding History

Cerity Partners’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$765K Sell
9,375
-1,481
-14% -$107K ﹤0.01% 2159
2026
Q1 		$740K Sell
10,856
-348
-3% -$24.6K ﹤0.01% 2045
2025
Q4 		$851K Buy
11,204
+964
+9% +$70.1K ﹤0.01% 1800
2025
Q3 		$628K Buy
10,240
+1,737
+20% +$90.5K ﹤0.01% 1842
2025
Q2 		$415K Sell
8,503
-4,078
-32% -$194K ﹤0.01% 1971
2025
Q1 		$641K Buy
+12,581
New +$628K ﹤0.01% 1636

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

Cerity Partners's PTCT Position: Q2 2026 in Review

Cerity Partners reduced its PTC Therapeutics (PTCT) stake by 14% in Q2 2026, selling an estimated $107K and leaving 9,375 shares worth $765K. The position accounts for ﹤0.01% of the portfolio, ranked #2159.

Cerity Partners first reported a position in PTCT in Q1 2025 and has held it in 6 quarters since. The position peaked at $851K in Q4 2025. 355 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • Cerity Partners held 9,375 shares of PTC Therapeutics worth $765K as of Q2 2026.
  • Cerity Partners sold 1,481 PTC Therapeutics shares in Q2 2026, an estimated $107K.
  • PTC Therapeutics made up ﹤0.01% of Cerity Partners's portfolio in Q2 2026, its #2159 holding.
  • Cerity Partners first reported a position in PTC Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • Cerity Partners's PTC Therapeutics position peaked at $851K in Q4 2025.
  • 355 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Cerity Partners's 13F filing for Q2 2026, filed 14 Aug 2026.